Skip to main content
. 2018 Jan 12;9(11):9741–9750. doi: 10.18632/oncotarget.24188

Figure 3. Best overall response rate during anti-HER2 therapy with exclusion of breast or oesogastric adenocarcinoma.

Figure 3

Best overall response rate was the greater disease in tumor volume under treatment assessed with RECISTS1.1. Patients with early clinical deterioration were arbitrarily put at the maximum observed increase.